Peanut Allergy - Market Insights, Epidemiology and Market Forecast-2028
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Peanut Allergy - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peanut Allergy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Peanut Allergy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Peanut Allergy - Disease Understanding
A peanut allergy is an allergic reaction to peanuts which occurs when the human body mistakenly identifies peanuts as harmful substances. Peanuts are not the same as tree nuts (almonds, cashews, walnuts, etc.), which grow on trees. In botanical terms, the peanut is not a nut, but a legume. It is one of the types of food that often provoke severe allergic reactions. In some cases, trace amounts of one milligram can trigger a reaction. In comparison, a peanut weighs between 500 and 1000 milligrams.
Peanut allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and the potential severity of the allergic reaction. Although other food allergies occurring in childhood usually resolve spontaneously with age, peanut sensitivity appears early in life and often persists indefinitely. Frequently, large quantities of peanut allergens are not needed to elicit an allergic reaction—even trace levels of peanut are capable of causing a hypersensitive reaction. Peanut allergy is estimated to affect 0.5–1.1% of the population, depending on the area studied.
Peanut-allergic individuals may experience symptoms ranging from mild urticaria, facial swelling, and abdominal cramp to hypertension with anaphylactic shock. In fact, it is the most common cause of fatal food-related anaphylaxis.
The DelveInsight Peanut Allergy market report gives a thorough understanding of the Peanut Allergy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Peanut Allergy in the US, Europe, and Japan.
Peanut Allergy Epidemiology
The Peanut Allergy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total prevalent population, age-specific prevalent population, gender-specific prevalent population and severity-specific prevalent population.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Peanut Allergy was estimated to be 8,693,872 [7MM] in 2018. United States accounts for the highest Peanut Allergy cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Peanut Allergy, followed by Germany.
Peanut Allergy Management
Currently, there is no standard of care for patients with Peanut Allergy, highlighting a pressing need to develop safe and effective curative interventions. The primary care of treatment, include antihistamines and injectible epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. However all these therapies are used as off-label therapies and there is no approved therapy yet for the treatment of Peanut Allergy
The primary care of treatment, include antihistamines and injectible epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. Antihistamines, known as H1 blockers, are beneficial for the treatment of acute mild reactions, (e.g., itching, sneezing, hives and rashes), although they cannot stop or control a severe reaction. Medications in this class include diphendydramine and cetirizine. Antihistamines do not treat anaphylaxis and have no life-saving capacity. Diphenhydramine has been commonly used as the antihistamine of choice for acute food allergic reactions given its prompt onset of action and ready availability, though epinephrine is still the first-line therapy for anaphylaxis. Cetirizine is a second generation antihistamine with a similar onset but longer duration of action (?24 hours) compared to diphenhydramine. Furthermore, CNS effects are less commonly reported. Cetirizine has been used by patients in outpatient clinic for the treatment of acute allergic food reactions. In order to meet the high unmet need of Peanut Allergy treatment regimen, companies across the globe have shifted their focus towards this therapeutic area. Recent studies show promise in the effectiveness and safety of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Additionally, improved diagnostic testing provides more accurate results while minimizing risk.
Peanut Allergy Market Outlook
The Peanut Allergy (PWS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Peanut Allergy (PWS) was estimated to be USD 3144.8 million in 2018. The United States accounts for the largest market size of Peanut Allergy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Peanut Allergy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The overall dynamics of Peanut Allergy market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Aimmune Therapeutics’ AR101, DBV Technologies’ Viaskin Peanut, AnaptysBio’s ANB020 and Genentech’s Omalizumab. Out of these emerging therapies, AR101 (Aimmune Therapeutics) is expected to be launched in 2019 in the US. Aimmune’s AR101 is expected to grab maximum market share, as it is currently in Phase III stage of clinical development with very good safety and eeficacy results, and will therefore influence the market size with a greater percentage. DBV Technologies’s Viaskin Peanut, although would be launched later than AR101, i.e. in 2020, but still is expected to provide a significant competition in the therapeutic market.
Peanut Allergy Report Insights
DelveInsight’s ‘Peanut Allergy - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peanut Allergy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Peanut Allergy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Peanut Allergy - Disease Understanding
A peanut allergy is an allergic reaction to peanuts which occurs when the human body mistakenly identifies peanuts as harmful substances. Peanuts are not the same as tree nuts (almonds, cashews, walnuts, etc.), which grow on trees. In botanical terms, the peanut is not a nut, but a legume. It is one of the types of food that often provoke severe allergic reactions. In some cases, trace amounts of one milligram can trigger a reaction. In comparison, a peanut weighs between 500 and 1000 milligrams.
Peanut allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and the potential severity of the allergic reaction. Although other food allergies occurring in childhood usually resolve spontaneously with age, peanut sensitivity appears early in life and often persists indefinitely. Frequently, large quantities of peanut allergens are not needed to elicit an allergic reaction—even trace levels of peanut are capable of causing a hypersensitive reaction. Peanut allergy is estimated to affect 0.5–1.1% of the population, depending on the area studied.
Peanut-allergic individuals may experience symptoms ranging from mild urticaria, facial swelling, and abdominal cramp to hypertension with anaphylactic shock. In fact, it is the most common cause of fatal food-related anaphylaxis.
The DelveInsight Peanut Allergy market report gives a thorough understanding of the Peanut Allergy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Peanut Allergy in the US, Europe, and Japan.
Peanut Allergy Epidemiology
The Peanut Allergy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by total prevalent population, age-specific prevalent population, gender-specific prevalent population and severity-specific prevalent population.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Peanut Allergy was estimated to be 8,693,872 [7MM] in 2018. United States accounts for the highest Peanut Allergy cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Peanut Allergy, followed by Germany.
Peanut Allergy Management
Currently, there is no standard of care for patients with Peanut Allergy, highlighting a pressing need to develop safe and effective curative interventions. The primary care of treatment, include antihistamines and injectible epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. However all these therapies are used as off-label therapies and there is no approved therapy yet for the treatment of Peanut Allergy
The primary care of treatment, include antihistamines and injectible epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. Antihistamines, known as H1 blockers, are beneficial for the treatment of acute mild reactions, (e.g., itching, sneezing, hives and rashes), although they cannot stop or control a severe reaction. Medications in this class include diphendydramine and cetirizine. Antihistamines do not treat anaphylaxis and have no life-saving capacity. Diphenhydramine has been commonly used as the antihistamine of choice for acute food allergic reactions given its prompt onset of action and ready availability, though epinephrine is still the first-line therapy for anaphylaxis. Cetirizine is a second generation antihistamine with a similar onset but longer duration of action (?24 hours) compared to diphenhydramine. Furthermore, CNS effects are less commonly reported. Cetirizine has been used by patients in outpatient clinic for the treatment of acute allergic food reactions. In order to meet the high unmet need of Peanut Allergy treatment regimen, companies across the globe have shifted their focus towards this therapeutic area. Recent studies show promise in the effectiveness and safety of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Additionally, improved diagnostic testing provides more accurate results while minimizing risk.
Peanut Allergy Market Outlook
The Peanut Allergy (PWS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Peanut Allergy (PWS) was estimated to be USD 3144.8 million in 2018. The United States accounts for the largest market size of Peanut Allergy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Peanut Allergy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The overall dynamics of Peanut Allergy market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Aimmune Therapeutics’ AR101, DBV Technologies’ Viaskin Peanut, AnaptysBio’s ANB020 and Genentech’s Omalizumab. Out of these emerging therapies, AR101 (Aimmune Therapeutics) is expected to be launched in 2019 in the US. Aimmune’s AR101 is expected to grab maximum market share, as it is currently in Phase III stage of clinical development with very good safety and eeficacy results, and will therefore influence the market size with a greater percentage. DBV Technologies’s Viaskin Peanut, although would be launched later than AR101, i.e. in 2020, but still is expected to provide a significant competition in the therapeutic market.
Peanut Allergy Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Peanut Allergy market.
- Organize sales and marketing efforts by identifying the best opportunities for Peanut Allergy market.
- To understand the future market competition in the Peanut Allergy market.
1 KEY INSIGHTS
2 PEANUT ALLERGY: MARKET OVERVIEW AT A GLANCE
2.1 Total Market Share (%) Distribution of Peanut Allergy in 2016
2.2 Total Market Share (%) Distribution of Peanut Allergy in 2027
3 PEANUT ALLERGY: DISEASE BACKGROUND AND OVERVIEW
3.1 Introduction
3.2 Peanut Allergans
3.2.1 Characterization of Peanut Allergans
3.3 Clinical Presentation
3.3.1 Clinical Symptoms
3.4 Causes and Risk Factors
3.4.1 Risk Factors
3.5 Pathophysiology of Peanut Allergy
3.6 Cross-reactivity with Other Foods
3.6.1 Outgrowing Peanut Allergy
3.7 Diagnosis of Peanut Allergy
3.7.1 History, the key Diagnostic Test
3.7.2 Skin Prick Tests (SPT)
3.7.3 Serum Peanut-IgE Concentration
3.7.4 Component Testing
3.7.5 Peanut-Induced Anaphylactic Reactions
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 Key Findings
5 TOTAL PREVALENT POPULATION OF PEANUT ALLERGY IN 7MM
6 UNITED STATES EPIDEMIOLOGY
6.1 Assumptions and Rationale
6.2 Total Prevalent Population of Peanut Allergy in the United States
6.3 Gender – Specific Prevalent Population of Peanut Allergy in the United States
6.4 Age – Specific Prevalent Population of Peanut Allergy in the United States
6.5 Severity – Specific Prevalent Population of Peanut Allergy in the United States
7 EU5 EPIDEMIOLOGY
7.1 Germany Epidemiology
7.1.1 Assumptions and Rationale
7.1.2 Total Prevalent Population of Peanut Allergy in Germany
7.1.3 Gender – Specific Prevalent Population of Peanut Allergy in Germany
7.1.4 Age – Specific Prevalent Population of Peanut Allergy in Germany
7.1.5 Severity – Specific Prevalent Population of Peanut Allergy in Germany
7.2 France Epidemiology
7.2.1 Assumptions and rationale
7.2.2 Total Prevalent Population of Peanut Allergy in France
7.2.3 Gender – Specific Prevalent Population of Peanut Allergy in France
7.2.4 Age – Specific Prevalent Population of Peanut Allergy in France
7.2.5 Severity – Specific Prevalent Population of Peanut Allergy in France
7.3 Italy Epidemiology
7.3.1 Assumptions and Rationale
7.3.2 Total Prevalent Population of Peanut Allergy in Italy
7.3.3 Gender – Specific Prevalent Population of Peanut Allergy in Italy
7.3.4 Age – Specific Prevalent Population of Peanut Allergy in Italy
7.3.5 Severity – Specific Prevalent Population of Peanut Allergy in Italy
7.4 Spain Epidemiology
7.4.1 Assumptions and Rationale
7.4.2 Total Prevalent Population of Peanut Allergy in Spain
7.4.3 Gender – Specific Prevalent Population of Peanut Allergy in Spain
7.4.4 Age – Specific Prevalent Population of Peanut Allergy in Spain
7.4.5 Severity – Specific Prevalent Population of Peanut Allergy in Spain
7.5 United Kingdom Epidemiology
7.5.1 Assumptions and Rationale
7.5.2 Total Prevalent Population of Peanut Allergy in the United Kingdom
7.5.3 Gender – Specific Prevalent Population of Peanut Allergy in the United Kingdom
7.5.4 Age – Specific Prevalent Population of Peanut Allergy in the United Kingdom
7.5.5 Severity – Specific Prevalent Population of Peanut Allergy in the United Kingdom
7.6 Japan Epidemiology
7.6.1 Assumptions and Rationale
7.6.2 Total Prevalent Population of Peanut Allergy in the Japan
7.6.3 Gender – Specific Prevalent Population of Peanut Allergy in the Japan
7.6.4 Age – Specific Prevalent Population of Peanut Allergy in Japan
7.6.5 Severity – Specific Prevalent Population of Peanut Allergy in the Japan
8 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
8.1 Primary Prevention
8.2 Management
8.3 Oral Immunotherapy
8.4 Treatment Guidelines
8.4.1 Practice Guidelines for Peanut Allergies
9 UNMET NEEDS
10 EMERGING THERAPIES
10.1 Key Cross Competition
10.2 AR101: Aimmune Therapeutics
10.2.1 Product Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Viaskin Peanut: DBV Technologies
10.3.1 Product Description
10.3.2 Other Developmental Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 ANB020: AnaptysBio
10.4.1 Drug Description
10.4.2 Other Developmental Activities
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 Omalizumab: Genentech
10.5.1 Drug Description
10.5.2 Other Developmental Activities
10.5.3 Clinical Development
10.5.4 Safety and Efficacy
10.5.5 Product Profile
11 PEANUT ALLERGY: 7MM MARKET ANALYSIS
11.1 Key Findings
11.1 Market Size of Peanut Allergy in 7MM
12 UNITED STATES: MARKET OUTLOOK
12.1 United States Market Size
12.1.1 Total Market size of Peanut Allergy
12.1.2 Market Size of Peanut Allergy by Therapies in the US
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 Germany Market Size
13.1.1 Total Market size of Peanut Allergy
13.1.2 Market Size of Peanut Allergy by therapies in Germany
13.2 France Market Size
13.2.1 Total Market size of Peanut Allergy
13.2.2 Market Size of Peanut Allergy by therapies in France
13.3 Italy Market Size
13.3.1 Total Market size of Peanut Allergy
13.3.2 Market Size of Peanut Allergy by therapies in Italy
13.4 Spain Market Size
13.4.1 Total Market size of Peanut Allergy
13.4.2 Market Size of Peanut Allergy by therapies in Spain
13.5 United Kingdom Market Size
13.5.1 Total Market size of Peanut Allergy
13.5.2 Market Size of Peanut Allergy by therapies in the UK
14 JAPAN MARKET OUTLOOK
14.1 Japan Market Size
14.1.1 Total Market size of Peanut Allergy
14.1.2 Market Size of Peanut Allergy by therapies in Japan
15 MARKET DRIVERS
16 MARKET BARRIERS
17 APPENDIX
17.1 Report Methodology
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
2 PEANUT ALLERGY: MARKET OVERVIEW AT A GLANCE
2.1 Total Market Share (%) Distribution of Peanut Allergy in 2016
2.2 Total Market Share (%) Distribution of Peanut Allergy in 2027
3 PEANUT ALLERGY: DISEASE BACKGROUND AND OVERVIEW
3.1 Introduction
3.2 Peanut Allergans
3.2.1 Characterization of Peanut Allergans
3.3 Clinical Presentation
3.3.1 Clinical Symptoms
3.4 Causes and Risk Factors
3.4.1 Risk Factors
3.5 Pathophysiology of Peanut Allergy
3.6 Cross-reactivity with Other Foods
3.6.1 Outgrowing Peanut Allergy
3.7 Diagnosis of Peanut Allergy
3.7.1 History, the key Diagnostic Test
3.7.2 Skin Prick Tests (SPT)
3.7.3 Serum Peanut-IgE Concentration
3.7.4 Component Testing
3.7.5 Peanut-Induced Anaphylactic Reactions
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 Key Findings
5 TOTAL PREVALENT POPULATION OF PEANUT ALLERGY IN 7MM
6 UNITED STATES EPIDEMIOLOGY
6.1 Assumptions and Rationale
6.2 Total Prevalent Population of Peanut Allergy in the United States
6.3 Gender – Specific Prevalent Population of Peanut Allergy in the United States
6.4 Age – Specific Prevalent Population of Peanut Allergy in the United States
6.5 Severity – Specific Prevalent Population of Peanut Allergy in the United States
7 EU5 EPIDEMIOLOGY
7.1 Germany Epidemiology
7.1.1 Assumptions and Rationale
7.1.2 Total Prevalent Population of Peanut Allergy in Germany
7.1.3 Gender – Specific Prevalent Population of Peanut Allergy in Germany
7.1.4 Age – Specific Prevalent Population of Peanut Allergy in Germany
7.1.5 Severity – Specific Prevalent Population of Peanut Allergy in Germany
7.2 France Epidemiology
7.2.1 Assumptions and rationale
7.2.2 Total Prevalent Population of Peanut Allergy in France
7.2.3 Gender – Specific Prevalent Population of Peanut Allergy in France
7.2.4 Age – Specific Prevalent Population of Peanut Allergy in France
7.2.5 Severity – Specific Prevalent Population of Peanut Allergy in France
7.3 Italy Epidemiology
7.3.1 Assumptions and Rationale
7.3.2 Total Prevalent Population of Peanut Allergy in Italy
7.3.3 Gender – Specific Prevalent Population of Peanut Allergy in Italy
7.3.4 Age – Specific Prevalent Population of Peanut Allergy in Italy
7.3.5 Severity – Specific Prevalent Population of Peanut Allergy in Italy
7.4 Spain Epidemiology
7.4.1 Assumptions and Rationale
7.4.2 Total Prevalent Population of Peanut Allergy in Spain
7.4.3 Gender – Specific Prevalent Population of Peanut Allergy in Spain
7.4.4 Age – Specific Prevalent Population of Peanut Allergy in Spain
7.4.5 Severity – Specific Prevalent Population of Peanut Allergy in Spain
7.5 United Kingdom Epidemiology
7.5.1 Assumptions and Rationale
7.5.2 Total Prevalent Population of Peanut Allergy in the United Kingdom
7.5.3 Gender – Specific Prevalent Population of Peanut Allergy in the United Kingdom
7.5.4 Age – Specific Prevalent Population of Peanut Allergy in the United Kingdom
7.5.5 Severity – Specific Prevalent Population of Peanut Allergy in the United Kingdom
7.6 Japan Epidemiology
7.6.1 Assumptions and Rationale
7.6.2 Total Prevalent Population of Peanut Allergy in the Japan
7.6.3 Gender – Specific Prevalent Population of Peanut Allergy in the Japan
7.6.4 Age – Specific Prevalent Population of Peanut Allergy in Japan
7.6.5 Severity – Specific Prevalent Population of Peanut Allergy in the Japan
8 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
8.1 Primary Prevention
8.2 Management
8.3 Oral Immunotherapy
8.4 Treatment Guidelines
8.4.1 Practice Guidelines for Peanut Allergies
9 UNMET NEEDS
10 EMERGING THERAPIES
10.1 Key Cross Competition
10.2 AR101: Aimmune Therapeutics
10.2.1 Product Description
10.2.2 Other Developmental Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Viaskin Peanut: DBV Technologies
10.3.1 Product Description
10.3.2 Other Developmental Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 ANB020: AnaptysBio
10.4.1 Drug Description
10.4.2 Other Developmental Activities
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 Omalizumab: Genentech
10.5.1 Drug Description
10.5.2 Other Developmental Activities
10.5.3 Clinical Development
10.5.4 Safety and Efficacy
10.5.5 Product Profile
11 PEANUT ALLERGY: 7MM MARKET ANALYSIS
11.1 Key Findings
11.1 Market Size of Peanut Allergy in 7MM
12 UNITED STATES: MARKET OUTLOOK
12.1 United States Market Size
12.1.1 Total Market size of Peanut Allergy
12.1.2 Market Size of Peanut Allergy by Therapies in the US
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 Germany Market Size
13.1.1 Total Market size of Peanut Allergy
13.1.2 Market Size of Peanut Allergy by therapies in Germany
13.2 France Market Size
13.2.1 Total Market size of Peanut Allergy
13.2.2 Market Size of Peanut Allergy by therapies in France
13.3 Italy Market Size
13.3.1 Total Market size of Peanut Allergy
13.3.2 Market Size of Peanut Allergy by therapies in Italy
13.4 Spain Market Size
13.4.1 Total Market size of Peanut Allergy
13.4.2 Market Size of Peanut Allergy by therapies in Spain
13.5 United Kingdom Market Size
13.5.1 Total Market size of Peanut Allergy
13.5.2 Market Size of Peanut Allergy by therapies in the UK
14 JAPAN MARKET OUTLOOK
14.1 Japan Market Size
14.1.1 Total Market size of Peanut Allergy
14.1.2 Market Size of Peanut Allergy by therapies in Japan
15 MARKET DRIVERS
16 MARKET BARRIERS
17 APPENDIX
17.1 Report Methodology
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Characteristics of Peanut Allergens
Table 2: Total Prevalent Population of Peanut Allergy in the 7MM (2016-2027)
Table 3: Total Prevalent Population of Peanut Allergy in the US (2016-2027)
Table 4: Gender Specific Prevalence of Peanut Allergy in the US (2016-2027)
Table 5: Age-Specific Prevalence of Peanut Allergy in the US (2016-2027)
Table 6: Severity Specific Prevalence of Peanut Allergy in the US (2016-2027)
Table 7: Total Prevalent Population of Peanut Allergy in Germany (2016-2027)
Table 8: Gender Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Table 9: Age-Specific Prevalence of Peanut Allergy in the Germany (2016-2027)
Table 10: Severity Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Table 11: Total Prevalent Population of Peanut Allergy in France (2016-2027)
Table 12: Gender Specific Prevalence of Peanut Allergy in France (2016-2027)
Table 13: Age-Specific Prevalence of Peanut Allergy in France (2016-2027)
Table 14: Severity Specific Prevalence of Peanut Allergy in France (2016-2027)
Table 15: Total Prevalent Population of Peanut Allergy in Italy (2016-2027)
Table 16: Gender Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Table 17: Age-Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Table 18: Severity Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Table 19: Total Prevalent Population of Peanut Allergy in Spain (2016-2027)
Table 20: Gender Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Table 21: Age-Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Table 22: Severity Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Table 23: Total Prevalent Population of Peanut Allergy in the UK (2016-2027)
Table 24: Gender Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Table 25: Age-Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Table 26: Severity Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Table 27: Total Prevalent Population of Peanut Allergy in Japan (2016-2027)
Table 28: Gender Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Table 29: Age-Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Table 30: Severity Specific Prevalence of Peanut Allergy in the Japan (2016-2027)
Table 31: Emerging Drugs Analysis
Table 32: Emerging Drugs Analysis - Continued
Table 33: AR101, Clinical Trial Description, 2018
Table 34: Viaskin Peanut, Clinical Trial Description, 2018
Table 35: ANB020, Clinical Trial Description, 2018
Table 36: Omalizumab, Clinical Trial Description, 2018
Table 37: Market Size of Peanut Allergy in 7MM in USD Million (2016-2027)
Table 38: The US Market Size of Peanut Allergy in USD Million (2016-2027)
Table 39: Market Size of Peanut Allergy by therapies in the US in USD Million (2016-2027)
Table 40: Germany Market Size of Peanut Allergy in USD Million (2016-2027)
Table 41: Market Size of Peanut Allergy by therapies in Germany in USD Million (2016-2027)
Table 42: France Market Size of Peanut Allergy in USD Million (2016-2027)
Table 43: Market Size of Peanut Allergy by therapies in France in USD Million (2016-2027)
Table 44: Italy Market Size of Peanut Allergy in USD Million (2016-2027)
Table 45: Market Size of Peanut Allergy by therapies in Italy in USD Million (2016-2027)
Table 46: Spain Market Size of Peanut Allergy in USD Million (2016-2027)
Table 47: Market Size of Peanut Allergy by therapies in Spain in USD Million (2016-2027)
Table 48: The UK Market Size of Peanut Allergy in USD Million (2016-2027)
Table 49: Market Size of Peanut Allergy by therapies in the UK in USD Million (2016-2027)
Table 50: Japan Market Size of Peanut Allergy in USD Million (2016-2027)
Table 51:Market Size of Peanut Allergy by therapies in Japan in USD Million (2016-2027)
Table 1: Characteristics of Peanut Allergens
Table 2: Total Prevalent Population of Peanut Allergy in the 7MM (2016-2027)
Table 3: Total Prevalent Population of Peanut Allergy in the US (2016-2027)
Table 4: Gender Specific Prevalence of Peanut Allergy in the US (2016-2027)
Table 5: Age-Specific Prevalence of Peanut Allergy in the US (2016-2027)
Table 6: Severity Specific Prevalence of Peanut Allergy in the US (2016-2027)
Table 7: Total Prevalent Population of Peanut Allergy in Germany (2016-2027)
Table 8: Gender Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Table 9: Age-Specific Prevalence of Peanut Allergy in the Germany (2016-2027)
Table 10: Severity Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Table 11: Total Prevalent Population of Peanut Allergy in France (2016-2027)
Table 12: Gender Specific Prevalence of Peanut Allergy in France (2016-2027)
Table 13: Age-Specific Prevalence of Peanut Allergy in France (2016-2027)
Table 14: Severity Specific Prevalence of Peanut Allergy in France (2016-2027)
Table 15: Total Prevalent Population of Peanut Allergy in Italy (2016-2027)
Table 16: Gender Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Table 17: Age-Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Table 18: Severity Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Table 19: Total Prevalent Population of Peanut Allergy in Spain (2016-2027)
Table 20: Gender Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Table 21: Age-Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Table 22: Severity Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Table 23: Total Prevalent Population of Peanut Allergy in the UK (2016-2027)
Table 24: Gender Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Table 25: Age-Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Table 26: Severity Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Table 27: Total Prevalent Population of Peanut Allergy in Japan (2016-2027)
Table 28: Gender Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Table 29: Age-Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Table 30: Severity Specific Prevalence of Peanut Allergy in the Japan (2016-2027)
Table 31: Emerging Drugs Analysis
Table 32: Emerging Drugs Analysis - Continued
Table 33: AR101, Clinical Trial Description, 2018
Table 34: Viaskin Peanut, Clinical Trial Description, 2018
Table 35: ANB020, Clinical Trial Description, 2018
Table 36: Omalizumab, Clinical Trial Description, 2018
Table 37: Market Size of Peanut Allergy in 7MM in USD Million (2016-2027)
Table 38: The US Market Size of Peanut Allergy in USD Million (2016-2027)
Table 39: Market Size of Peanut Allergy by therapies in the US in USD Million (2016-2027)
Table 40: Germany Market Size of Peanut Allergy in USD Million (2016-2027)
Table 41: Market Size of Peanut Allergy by therapies in Germany in USD Million (2016-2027)
Table 42: France Market Size of Peanut Allergy in USD Million (2016-2027)
Table 43: Market Size of Peanut Allergy by therapies in France in USD Million (2016-2027)
Table 44: Italy Market Size of Peanut Allergy in USD Million (2016-2027)
Table 45: Market Size of Peanut Allergy by therapies in Italy in USD Million (2016-2027)
Table 46: Spain Market Size of Peanut Allergy in USD Million (2016-2027)
Table 47: Market Size of Peanut Allergy by therapies in Spain in USD Million (2016-2027)
Table 48: The UK Market Size of Peanut Allergy in USD Million (2016-2027)
Table 49: Market Size of Peanut Allergy by therapies in the UK in USD Million (2016-2027)
Table 50: Japan Market Size of Peanut Allergy in USD Million (2016-2027)
Table 51:Market Size of Peanut Allergy by therapies in Japan in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Clinical Symptoms of Peanut Allergy
Figure 2: Peanut Allergy Risk Factors
Figure 3: Peanut activation of complement exacerbates anaphylaxis
Figure 4: Total Prevalent Population of Peanut Allergy in the 7MM (2016-2027)
Figure 5: Total Prevalent Population of Peanut Allergy in the US (2016-2027)
Figure 6: Gender Specific Prevalence of Peanut Allergy in the US (2016-2027)
Figure 7: Age-Specific Prevalence of Peanut Allergy in the US (2016-2027)
Figure 8: Severity Specific Prevalence of Peanut Allergy in the US (2016-2027)
Figure 9: Total Prevalent Population of Peanut Allergy in Germany (2016-2027)
Figure 10: Gender Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Figure 11: Age-Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Figure 12: Severity Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Figure 13: Total Prevalent Population of Peanut Allergy in France (2016-2027)
Figure 14: Gender Specific Prevalence of Peanut Allergy in France (2016-2027)
Figure 15: Age-Specific Prevalence of Peanut Allergy in France (2016-2027)
Figure 16: Severity Specific Prevalence of Peanut Allergy in France (2016-2027)
Figure 17: Total Prevalent Population of Peanut Allergy in Italy (2016-2027)
Figure 18: Gender Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Figure 19: Age-Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Figure 20: Severity Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Figure 21: Total Prevalent Population of Peanut Allergy in Spain (2016-2027)
Figure 22: Gender Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Figure 23: Age-Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Figure 24: Severity Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Figure 25: Total Prevalent Population of Peanut Allergy in the UK (2016-2027)
Figure 26: Gender Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Figure 27: Age-Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Figure 28: Severity Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Figure 29: Total Prevalent Population of Peanut Allergy in Japan (2016-2027)
Figure 30: Gender Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Figure 31: Age-Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Figure 32: Severity Specific Prevalence of Peanut Allergy in the Japan (2016-2027)
Figure 33: Algorithm for Peanut Allergy treatment
Figure 34: Unmet Needs of Peanut Allergy
Figure 35: Market Size of Peanut Allergy in the 7MM in USD Million (2016-2027)
Figure 36: Market Size of Peanut Allergy in the US, USD Millions (2016-2027)
Figure 37: Market Size of Peanut Allergy by therapies in the United States in USD Million (2016-2027)
Figure 38: Market Size of Peanut Allergy in Germany, USD Millions (2016-2027)
Figure 39: Market Size of Peanut Allergy by therapies in Germany in USD Million (2016-2027)
Figure 40: Market Size of Peanut Allergy in France, USD Millions (2016-2027)
Figure 41: Market Size of Peanut Allergy by therapies in France in USD Million (2016-2027)
Figure 42: Market Size of Peanut Allergy in Italy, USD Millions (2016-2027)
Figure 43: Market Size of Peanut Allergy by therapies in Italy in USD Million (2016-2027)
Figure 44: Market Size of Peanut Allergy in Spain, USD Millions (2016-2027)
Figure 45: Market Size of Peanut Allergy by therapies in Spain in USD Million (2016-2027)
Figure 46: Market Size of Peanut Allergy in the UK, USD Millions (2016-2027)
Figure 47: Market Size of Peanut Allergy by therapies in the UK in USD Million (2016-2027)
Figure 48: Market Size of Peanut Allergy in the Japan, USD Millions (2016-2027)
Figure 49: Market Size of Peanut Allergy by therapies in Japan in USD Million (2016-2027)
Figure 50: Market Drivers
Figure 51:Market Barriers
Figure 1: Clinical Symptoms of Peanut Allergy
Figure 2: Peanut Allergy Risk Factors
Figure 3: Peanut activation of complement exacerbates anaphylaxis
Figure 4: Total Prevalent Population of Peanut Allergy in the 7MM (2016-2027)
Figure 5: Total Prevalent Population of Peanut Allergy in the US (2016-2027)
Figure 6: Gender Specific Prevalence of Peanut Allergy in the US (2016-2027)
Figure 7: Age-Specific Prevalence of Peanut Allergy in the US (2016-2027)
Figure 8: Severity Specific Prevalence of Peanut Allergy in the US (2016-2027)
Figure 9: Total Prevalent Population of Peanut Allergy in Germany (2016-2027)
Figure 10: Gender Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Figure 11: Age-Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Figure 12: Severity Specific Prevalence of Peanut Allergy in Germany (2016-2027)
Figure 13: Total Prevalent Population of Peanut Allergy in France (2016-2027)
Figure 14: Gender Specific Prevalence of Peanut Allergy in France (2016-2027)
Figure 15: Age-Specific Prevalence of Peanut Allergy in France (2016-2027)
Figure 16: Severity Specific Prevalence of Peanut Allergy in France (2016-2027)
Figure 17: Total Prevalent Population of Peanut Allergy in Italy (2016-2027)
Figure 18: Gender Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Figure 19: Age-Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Figure 20: Severity Specific Prevalence of Peanut Allergy in Italy (2016-2027)
Figure 21: Total Prevalent Population of Peanut Allergy in Spain (2016-2027)
Figure 22: Gender Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Figure 23: Age-Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Figure 24: Severity Specific Prevalence of Peanut Allergy in Spain (2016-2027)
Figure 25: Total Prevalent Population of Peanut Allergy in the UK (2016-2027)
Figure 26: Gender Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Figure 27: Age-Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Figure 28: Severity Specific Prevalence of Peanut Allergy in the UK (2016-2027)
Figure 29: Total Prevalent Population of Peanut Allergy in Japan (2016-2027)
Figure 30: Gender Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Figure 31: Age-Specific Prevalence of Peanut Allergy in Japan (2016-2027)
Figure 32: Severity Specific Prevalence of Peanut Allergy in the Japan (2016-2027)
Figure 33: Algorithm for Peanut Allergy treatment
Figure 34: Unmet Needs of Peanut Allergy
Figure 35: Market Size of Peanut Allergy in the 7MM in USD Million (2016-2027)
Figure 36: Market Size of Peanut Allergy in the US, USD Millions (2016-2027)
Figure 37: Market Size of Peanut Allergy by therapies in the United States in USD Million (2016-2027)
Figure 38: Market Size of Peanut Allergy in Germany, USD Millions (2016-2027)
Figure 39: Market Size of Peanut Allergy by therapies in Germany in USD Million (2016-2027)
Figure 40: Market Size of Peanut Allergy in France, USD Millions (2016-2027)
Figure 41: Market Size of Peanut Allergy by therapies in France in USD Million (2016-2027)
Figure 42: Market Size of Peanut Allergy in Italy, USD Millions (2016-2027)
Figure 43: Market Size of Peanut Allergy by therapies in Italy in USD Million (2016-2027)
Figure 44: Market Size of Peanut Allergy in Spain, USD Millions (2016-2027)
Figure 45: Market Size of Peanut Allergy by therapies in Spain in USD Million (2016-2027)
Figure 46: Market Size of Peanut Allergy in the UK, USD Millions (2016-2027)
Figure 47: Market Size of Peanut Allergy by therapies in the UK in USD Million (2016-2027)
Figure 48: Market Size of Peanut Allergy in the Japan, USD Millions (2016-2027)
Figure 49: Market Size of Peanut Allergy by therapies in Japan in USD Million (2016-2027)
Figure 50: Market Drivers
Figure 51:Market Barriers
